420 related articles for article (PubMed ID: 12957195)
1. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life.
Djavan B
Urology; 2003 Sep; 62(3 Suppl 1):6-14. PubMed ID: 12957195
[TBL] [Abstract][Full Text] [Related]
2. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
O'Leary MP
Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
[TBL] [Abstract][Full Text] [Related]
3. Initial choices and final outcomes in lower urinary tract symptoms.
Speakman MJ
Eur Urol; 2001; 40 Suppl 4():21-30. PubMed ID: 11786676
[TBL] [Abstract][Full Text] [Related]
4. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
Schulman CC
Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
[TBL] [Abstract][Full Text] [Related]
5. Lower urinary tract symptoms: what are the implications for the patients?
Scarpa RM
Eur Urol; 2001; 40 Suppl 4():12-20. PubMed ID: 11786675
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
7. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
Nickel JC
Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
[TBL] [Abstract][Full Text] [Related]
8. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
Dunn CJ; Matheson A; Faulds DM
Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
Ryu YW; Lim SW; Kim JH; Ahn SH; Choi JD
Urol Int; 2015; 94(2):187-93. PubMed ID: 25614155
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
Lojanapiwat B; Permpongkosol S
Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy and quality of life.
Chapple CR
Eur Urol; 1998; 34 Suppl 2():10-7; discussion 46. PubMed ID: 9732824
[TBL] [Abstract][Full Text] [Related]
15. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia. Practical treatment guidelines.
Tammela T
Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
18. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
20. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
